Profile data is unavailable for this security.
About the company
Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of women’s health. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.
- Revenue in SEK (TTM)0.00
- Net income in SEK-12.83m
- Incorporated2006
- Employees2.00
- LocationAsarina Pharma AB (publ)Karolinska Institutet Science ParkFogdevreten 2SOLNA 171 65SwedenSWE
- Phone+46 852484482
- Websitehttps://asarinapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Asarina Pharma AB (publ) | 0.00 | -12.83m | 1.15m | 2.00 | -- | 0.7003 | -- | -- | -0.5666 | -0.5666 | 0.00 | 0.0728 | 0.00 | -- | -- | 0.00 | -111.87 | -61.25 | -157.85 | -71.89 | -- | -- | -- | -- | -- | -- | 0.3775 | -- | -- | -- | 3.43 | -- | -- | -- |
Neovacs SA | 6.04m | -99.05m | 1.71m | 22.00 | -- | 0.00 | -- | 0.2834 | -30,639.66 | -30,639.66 | 1.52 | 138.89 | 0.0099 | -- | 1.84 | 24,245.91 | -16.21 | -24.42 | -17.66 | -28.28 | 5.50 | -232.13 | -1,639.16 | -6,444.71 | -- | -- | 0.0131 | -- | 47,954.95 | -- | -146.40 | -- | 82.72 | -- |
Paion AG | -1.13tn | -1.13tn | 1.80m | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |
European Institute of Science AB | 764.87k | -2.65m | 1.87m | 2.00 | -- | 2.82 | -- | 2.45 | -3.95 | -3.95 | 1.13 | 1.23 | 0.3042 | 1.80 | 5.71 | 382,435.00 | -105.50 | -93.04 | -115.57 | -103.14 | 54.58 | 66.99 | -346.76 | -518.86 | 8.19 | -- | 0.00 | -- | 13.66 | 8.54 | 0.3974 | -- | -- | -- |
Theravet SA | -1.13tn | -1.13tn | 3.57m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Diagonal Bio AB | 23.00k | -11.62m | 4.09m | 4.00 | -- | 0.145 | -- | 177.67 | -0.1407 | -0.1407 | 0.0002 | 0.0704 | 0.0008 | -- | 2.00 | 4,600.00 | -38.99 | -- | -43.85 | -- | -32,443.48 | -- | -50,504.35 | -- | 1.72 | -15.50 | 0.00 | -- | -88.67 | -- | 27.75 | -- | -- | -- |